Cogent Biosciences Inc. (COGT)
4.22
-0.15 (-3.43%)
At close: Apr 21, 2025, 3:59 PM
4.30
1.78%
After-hours: Apr 21, 2025, 04:33 PM EDT
-3.43% (1D)
| Bid | 4.21 |
| Market Cap | 481.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -255.86M |
| EPS (ttm) | -1.94 |
| PE Ratio (ttm) | -2.18 |
| Forward PE | -2.34 |
| Analyst | Buy |
| Ask | 4.39 |
| Volume | 620,860 |
| Avg. Volume (20D) | 1,421,839 |
| Open | 4.25 |
| Previous Close | 4.37 |
| Day's Range | 4.21 - 4.38 |
| 52-Week Range | 3.72 - 12.61 |
| Beta | 0.20 |
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon ...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2018
Employees 205
Stock Exchange NASDAQ
Ticker Symbol COGT
Website https://www.cogentbio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for COGT stock is "Buy." The 12-month stock price forecast is $14.5, which is an increase of 243.20% from the latest price.
Stock Forecasts5 months ago
-15.84%
Cogent Biosciences shares are trading lower after ...
Unlock content with
Pro Subscription
10 months ago
-6.12%
Cogent Biosciences shares are trading lower. The company announced additional data from Part 1 of its ongoing SUMMIT clinical trial evaluating the selective KIT D816V inhibitor, bezuclastinib, in patients with nonadvanced systemic mastocytosis.
